koko体育app

欢迎来到《koko体育app 学报（医学版）》
王瀚, 王跃龙, 刘志勇, 等. 颅内肿瘤的靶向药物治疗[J]. koko体育app 学报（医学版）, 2022, 53(4): 564-572. DOI:
引用本文: 王瀚, 王跃龙, 刘志勇, 等. 颅内肿瘤的靶向药物治疗[J]. koko体育app 学报（医学版）, 2022, 53(4): 564-572. DOI:
WANG Han, WANG Yue-long, LIU Zhi-yong, et al. Targeted Drug Therapy for Intracranial Tumors[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(4): 564-572. DOI:
Citation: 💧 WANG Han, WANG Yue-long, LIU Zhi-yong, et al. Targeted Drug Therapy for Intracranial Tumors[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(4): 564-572. DOI:

颅内肿瘤的靶向药物治疗

Targeted Drug Therapy for Intracranial Tumors

  • 摘要: 颅内肿瘤严重影响了人类的身心健康，由于肿瘤的性质与生长部位的不同，因此对颅内肿瘤患者进行个体化、特异性的治疗已成为当下研究的热点，而颅内肿瘤的靶向药物治疗作为精准医学的重要分支，更是成为了科学家重点攻坚的对象。目前分子生物学及基因组学的迅速发展，为肿瘤的精准治疗提供了相应的靶点。但是由于血脑屏障、血肿瘤屏障阻碍了药物到达颅内靶点，因此如何提升颅内药物浓度成为了目前靶向治疗颅内肿瘤的关键所在。本文总结了不同颅内肿瘤的靶向药物治疗的现状，探讨了对于不同颅内肿瘤靶向药物治疗的效果，以期为未来靶向药物对颅内肿瘤的治疗提供新的思考。  
    Abstract: Intracranial tumors seriously affect the physical and mental health of humans. Due to variations in the nature and the growth site of tumors, individualized and specific treatment of patients with intracranial tumor has become a hotspot topic of research, and targeted drug therapy of intracranial tumors, an important subspecialty of precision medicine, has become a key issue that scientists are working hard to tackle. At present, the rapid development in molecular biology and genomics has provided corresponding targets for precision therapies of tumors. However, the blood-brain barrier and blood-tumor barrier prevent drugs from reaching intracranial targets. Therefore, finding effective ways to elevate the concentration of intracranial drugs has become the key issue concerning existing targeted therapies for intracranial tumors. Herein, we reviewed the current status of targeted drug therapy for different intracranial tumors and discussed their efficacy, intending to provide new perspectives for the treatment of intracranial tumors with targeted drugs in the future.  
    • HTML全文
© 2022 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取ꦦ 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!